

Middle East and Africa Generic Drugs Market Report and Forecast 2024-2032

Market Report | 2024-07-19 | 180 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$3999.00
- Five User License \$5299.00
- Corporate License \$6299.00

Report description:

Middle East and Africa Generic Drugs Market Report and Forecast 2024-2032

The Middle East and Africa generic drugs market size was valued at USD 35.5 billion in 2023. It is expected to grow at a CAGR of 6.70% during the forecast period of 2024-2032, driven by the growing affordability of generic drugs. The market is experiencing robust growth and is expected to reach USD 64 billion by 2032.

Middle East and Africa Generic Drugs Market Analysis

The generic drugs market in the Middle East and Africa (MEA) is experiencing significant growth. Generics offer cost-effective alternatives to branded drugs, making them crucial in regions with constrained healthcare budgets and growing populations.

Market Drivers

- ☐ **Cost-Effectiveness and Affordability:** Generics are substantially cheaper than branded medications, making them more accessible to a larger portion of the population. This affordability is particularly important in MEA, where healthcare resources are often limited.
- ☐ **Rising Prevalence of Chronic Diseases:** The increasing incidence of chronic diseases such as diabetes, hypertension, and cardiovascular conditions is driving demand for long-term medication, which generics can provide more economically.
- ☐ **Government Initiatives and Policies:** Many MEA governments are implementing policies to promote the use of generics, including price regulations, subsidies, and initiatives to increase local production. These policies aim to reduce healthcare costs and improve access to essential medications.
- ☐ **Expansion of Healthcare Infrastructure:** The ongoing expansion and modernization of healthcare infrastructure in MEA countries are increasing the demand for affordable medicines, with generics playing a vital role in these developments.
- ☐ **Patent Expirations:** The expiration of patents on several blockbuster drugs opens the market for generic manufacturers to produce and sell lower-cost versions, further driving market growth.

Market Challenges

- ☐ **Regulatory Hurdles:** The regulatory environment in many MEA countries can be complex and inconsistent, posing challenges for generic drug approvals and market entry. This can lead to delays and increased costs for manufacturers.
- ☐ **Quality Concerns:** There are ongoing concerns about the quality and efficacy of generic drugs in some MEA markets. Ensuring consistent quality and building trust among healthcare providers and patients are critical challenges.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

-☐Intellectual Property Issues: Navigating intellectual property rights and patent laws can be challenging, with potential legal battles over patent infringements and disputes delaying market entry for generics.

-☐Market Competition: The generic drugs market is highly competitive, with numerous local and international players. This competition can drive down prices, impacting profit margins for manufacturers.

-☐Limited Awareness and Acceptance: In some regions, there is limited awareness and acceptance of generic drugs among healthcare providers and patients, who may prefer branded drugs due to perceived differences in quality and efficacy.

Future Opportunities

-☐Local Manufacturing and Partnerships: Increasing local manufacturing capabilities through investments and partnerships can help reduce costs, ensure consistent supply, and address regulatory and quality concerns. Collaborations between local companies and international pharmaceutical firms can be mutually beneficial.

-☐Government Support and Incentives: Continued government support in the form of incentives, subsidies, and streamlined regulatory processes can further boost the generic drugs market. Public awareness campaigns to promote the benefits and safety of generics can also enhance market acceptance.

-☐Technological Advancements: Leveraging advancements in pharmaceutical manufacturing technologies can improve the quality and efficiency of generic drug production. Innovations in formulation and drug delivery systems can also differentiate products in the competitive market.

Middle East and Africa Generic Drugs Market Trends

Here are some trends in the Middle East and Africa generic drugs market:

-☐Increasing Government Support and Policies

Governments in the Middle East and Africa are increasingly implementing policies to promote the use of generic drugs. This includes price regulation, mandatory generic substitution, and incentives for local manufacturing. These initiatives aim to reduce healthcare costs and improve access to essential medications.

-☐Rising Healthcare Expenditure

As economies in the region grow, there is a corresponding increase in healthcare expenditure. Governments and private sectors are investing more in healthcare infrastructure and services, leading to higher demand for affordable generic drugs to manage budgets effectively.

-☐Growing Prevalence of Chronic Diseases

The region is experiencing a significant rise in chronic diseases such as diabetes, hypertension, and cardiovascular diseases. This has increased the demand for long-term medication, where generics provide a cost-effective solution, thereby driving market growth.

-☐Expansion of Local Manufacturing

There is a notable trend towards expanding local manufacturing capabilities. This reduces dependency on imports, lowers costs, and ensures a more consistent supply of generic drugs. Governments are encouraging this trend through various incentives and supportive policies.

-☐Patent Expirations

The expiration of patents for several high-demand branded drugs is opening up opportunities for generic manufacturers. This trend allows for the introduction of cost-effective generic alternatives, driving market expansion.

Middle East and Africa Generic Drugs Market Segmentation

Market Breakup by Therapy Area

-☐Cardiovascular

-☐Dermatology

-☐Respiratory

-☐Oncology

-☐Rheumatology

-☐Others

The Middle East and Africa generic drugs market is segmented by therapy area into cardiovascular, dermatology, respiratory,

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

oncology, rheumatology, and others. The cardiovascular and oncology segments are experiencing significant growth due to high prevalence rates and the expiration of patents on major drugs. Dermatology and respiratory segments are benefiting from the increasing incidence of skin conditions and respiratory disorders, respectively, which drives the demand for cost-effective treatments. The rheumatology segment is poised for growth due to rising cases of arthritis and autoimmune diseases. Other segments, including neurology and infectious diseases, are also contributing to market expansion. Collectively, these segments drive market growth by providing affordable alternatives to branded medications during the forecast period.

Market Breakup by Route of Administration

- Oral
- Injectables
- Dermal/Topical
- Inhalers
- Others

The Middle East and Africa generic drugs market is segmented by route of administration into oral, injectables, dermal/topical, inhalers, and others. Oral generics dominate the market due to their ease of administration and high patient compliance, significantly driving market growth. The injectables segment is expanding rapidly, supported by advancements in biologics and biosimilars. Dermal/topical applications are in increasing demand due to the rising incidence of skin conditions and a preference for localized treatments. Inhalers are benefiting from the growing prevalence of respiratory disorders such as asthma and COPD. Other routes, including transdermal and nasal, contribute to market diversity. These segments collectively enhance market growth by offering a wide range of affordable and accessible treatment options during the forecast period.

Market Breakup by Distribution Channels

- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others

The Middle East and Africa generic drugs market is segmented by distribution channels into hospital pharmacy, retail pharmacy, online pharmacy, and others. Hospital pharmacies lead the market due to the high demand for cost-effective generic medications in both inpatient and outpatient settings. Retail pharmacies also play a significant role, benefiting from their widespread accessibility and consumer trust. Online pharmacies are rapidly expanding, driven by the convenience of home delivery and the increasing adoption of digital health solutions. Other channels, such as specialty pharmacies, also contribute to market distribution. Collectively, these segments enhance the accessibility and availability of affordable generic drugs, driving market growth during the forecast period.

Market Breakup by Country

- UAE
- Saudi Arabia
- Egypt
- Others

The Middle East and Africa generic drugs market is segmented by country into the UAE, Saudi Arabia, Egypt, and others. The UAE and Saudi Arabia lead the market, driven by advanced healthcare infrastructure, supportive government policies, and high demand for cost-effective treatments. Egypt shows strong growth potential due to its large population and ongoing healthcare reforms. Other countries in the region are also contributing, with increasing investments in healthcare and rising awareness of generics. These countries collectively drive market growth by enhancing the accessibility and affordability of generic drugs, positioning the market for significant expansion during the forecast period.

Middle East and Africa Generic Drugs Market Competitive Landscape

The competitive landscape of the Middle East and Africa generic drugs market includes key players such as Teva Pharmaceutical

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Industries Ltd, Viatri Inc., Sun Pharmaceutical Industries Ltd, Lupin, AstraZeneca, Baxter, Takeda Pharmaceutical Company Limited, GSK plc, Bausch + Lomb, Novartis AG, Sanofi, Pfizer Inc., Fresenius SE & Co. KGaA, Hikma Pharmaceuticals PLC, and Aurobindo Pharma. Common market activities among these companies include mergers and acquisitions to expand their market presence, extensive research initiatives to develop innovative generic drugs, frequent product introductions to meet diverse medical needs, and strategic partnerships to enhance R&D capabilities and market reach. These activities collectively drive growth and competition in the European generic drugs market.

Key Questions Answered in the Report

□What is the current and future performance of the generic drugs market?

□What are the main challenges facing the generic drugs market?

□What are the key drivers of the generic drugs market?

□What emerging trends are shaping the future of the generic drugs market?

□How do the increasing incidence of skin conditions and respiratory disorders impact the demand for generic treatments in dermatology and respiratory segments?

□Why do oral generics dominate the Middle East and Africa generic drugs market, and how do they drive market growth?

□What are the common strategies used by key players in the generic drugs market?

Key Benefits for Stakeholders

□The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the Middle East and Africa generic drugs market from 2017-2032.

□The research report provides the latest information on the market drivers, challenges, and opportunities in the generic drugs market.

□The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.

□Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the Middle East and Africa generic drugs industry and its attractiveness.

□The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.

Table of Contents:

- 1 Preface
 - 1.1 Objectives of the Study
 - 1.2 Key Assumptions
 - 1.3 Report Coverage - Key Segmentation and Scope
 - 1.4 Research Methodology
- 2 Executive Summary
- 3 Middle East and Africa Generic Drugs Market Overview
 - 3.1 Middle East and Africa Generic Drugs Market Historical Value (2017-2023)
 - 3.2 Middle East and Africa Generic Drugs Market Forecast Value (2024-2032)
- 4 Middle East and Africa Generic Drugs Market Landscape*
 - 4.1 Middle East and Africa Generic Drugs: Developers Landscape
 - 4.1.1 Analysis by Year of Establishment
 - 4.1.2 Analysis by Company Size
 - 4.1.3 Analysis by Region
 - 4.2 Middle East and Africa Generic Drugs: Product Landscape
 - 4.2.1 Analysis by Therapy Area
 - 4.2.2 Analysis by Route of Administration

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 4.2.3 Analysis by Distribution Channels
- 5 Middle East and Africa Generic Drugs Market Dynamics
 - 5.1 Market Drivers and Constraints
 - 5.2 SWOT Analysis
 - 5.2.1 Strengths
 - 5.2.2 Weaknesses
 - 5.2.3 Opportunities
 - 5.2.4 Threats
 - 5.3 Porter's Five Forces Model
 - 5.3.1 Bargaining Power of Suppliers
 - 5.3.2 Bargaining Power of Buyers
 - 5.3.3 Threat of New Entrants
 - 5.3.4 Threat of Substitutes
 - 5.3.5 Degree of Rivalry
 - 5.4 Key Demand Indicators
 - 5.5 Key Price Indicators
 - 5.6 Industry Events, Initiatives, and Trends
 - 5.7 Value Chain Analysis
- 6 Middle East and Africa Generic Drugs Market Segmentation (2017-2032)
 - 6.1 Middle East and Africa Generic Drugs Market (2017-2032) by Therapy Area
 - 6.1.1 Market Overview
 - 6.1.2 Cardiovascular
 - 6.1.3 Dermatology
 - 6.1.4 Respiratory
 - 6.1.5 Oncology
 - 6.1.6 Rheumatology
 - 6.1.7 Others
 - 6.2 Middle East and Africa Generic Drugs Market (2017-2032) by Route of Administration
 - 6.2.1 Market Overview
 - 6.2.2 Oral
 - 6.2.3 Injectables
 - 6.2.4 Dermal/Topical
 - 6.2.5 Inhalers
 - 6.2.6 Others
 - 6.3 Middle East and Africa Generic Drugs Market (2017-2032) by Distribution Channels
 - 6.3.1 Market Overview
 - 6.3.2 Hospital Pharmacy
 - 6.3.3 Retail Pharmacy
 - 6.3.4 Online Pharmacy
 - 6.3.5 Others
 - 6.4 Middle East and Africa Generic Drugs Market (2017-2032) by Country
 - 6.4.1 Market Overview
 - 6.4.2 UAE
 - 6.4.3 Saudi Arabia
 - 6.4.4 Egypt
 - 6.4.5 Others
- 7 UAE Generic Drugs Market Segmentation (2017-2032)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 7.1 UAE Generic Drugs Market (2017-2032) by Therapy Area
 - 7.1.1 Market Overview
 - 7.1.2 Cardiovascular
 - 7.1.3 Dermatology
 - 7.1.4 Respiratory
 - 7.1.5 Oncology
 - 7.1.6 Rheumatology
 - 7.1.7 Others
- 7.2 UAE Generic Drugs Market (2017-2032) by Route of Administration
 - 7.2.1 Market Overview
 - 7.2.2 Oral
 - 7.2.3 Injectables
 - 7.2.4 Dermal/Topical
 - 7.2.5 Inhalers
 - 7.2.6 Others
- 8 Saudi Arabia Generic Drugs Market Segmentation (2017-2032)
 - 8.1 Saudi Arabia Generic Drugs Market (2017-2032) by Therapy Area
 - 8.1.1 Market Overview
 - 8.1.2 Cardiovascular
 - 8.1.3 Dermatology
 - 8.1.4 Respiratory
 - 8.1.5 Oncology
 - 8.1.6 Rheumatology
 - 8.1.7 Others
 - 8.2 Saudi Arabia Generic Drugs Market (2017-2032) by Route of Administration
 - 8.2.1 Market Overview
 - 8.2.2 Oral
 - 8.2.3 Injectables
 - 8.2.4 Dermal/Topical
 - 8.2.5 Inhalers
 - 8.2.6 Others
- 9 Egypt Generic Drugs Market Segmentation (2017-2032)
 - 9.1 Egypt Generic Drugs Market (2017-2032) by Therapy Area
 - 9.1.1 Market Overview
 - 9.1.2 Cardiovascular
 - 9.1.3 Dermatology
 - 9.1.4 Respiratory
 - 9.1.5 Oncology
 - 9.1.6 Rheumatology
 - 9.1.7 Others
 - 9.2 Egypt Generic Drugs Market (2017-2032) by Route of Administration
 - 9.2.1 Market Overview
 - 9.2.2 Oral
 - 9.2.3 Injectables
 - 9.2.4 Dermal/Topical
 - 9.2.5 Inhalers
 - 9.2.6 Others

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 10 Regulatory Framework
 - 10.1 Regulatory Overview
 - 10.1.1 MOHAP UAE
 - 10.1.2 SFDA Saudi Arabia
- 11 Patent Analysis
 - 11.1 Analysis by Type of Patent
 - 11.2 Analysis by Publication year
 - 11.3 Analysis by Issuing Authority
 - 11.4 Analysis by Patent Age
 - 11.5 Analysis by CPC Analysis
 - 11.6 Analysis by Patent Valuation
 - 11.7 Analysis by Key Players
- 12 Grants Analysis
 - 12.1 Analysis by Year
 - 12.2 Analysis by Amount Awarded
 - 12.3 Analysis by Issuing Authority
 - 12.4 Analysis by Grant Housing Material
 - 12.5 Analysis by Funding Institute
 - 12.6 Analysis by Departments
 - 12.7 Analysis by Recipient Organization
- 13 Funding and Investment Analysis
 - 13.1 Analysis by Funding Instances
 - 13.2 Analysis by Type of Funding
 - 13.3 Analysis by Funding Amount
 - 13.4 Analysis by Leading Players
 - 13.5 Analysis by Leading Investors
 - 13.6 Analysis by Geography
- 14 Partnership and Collaborations Analysis
 - 14.1 Analysis by Partnership Instances
 - 14.2 Analysis by Type of Partnership
 - 14.3 Analysis by Leading Players
 - 14.4 Analysis by Geography
- 15 Supplier Landscape
 - 15.1 Market Share by Top 5 Companies
 - 15.2 Teva Pharmaceutical Industries Ltd
 - 15.2.1 Financial Analysis
 - 15.2.2 Product Portfolio
 - 15.2.3 Demographic Reach and Achievements
 - 15.2.4 Mergers and Acquisitions
 - 15.2.5 Certifications
 - 15.3 Viartis Inc.
 - 15.3.1 Financial Analysis
 - 15.3.2 Product Portfolio
 - 15.3.3 Demographic Reach and Achievements
 - 15.3.4 Mergers and Acquisitions
 - 15.3.5 Certifications
 - 15.4 AstraZeneca

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 15.4.1 Financial Analysis
- 15.4.2 Product Portfolio
- 15.4.3 Demographic Reach and Achievements
- 15.4.4 Mergers and Acquisitions
- 15.4.5 Certifications
- 15.5 Baxter
 - 15.5.1 Financial Analysis
 - 15.5.2 Product Portfolio
 - 15.5.3 Demographic Reach and Achievements
 - 15.5.4 Mergers and Acquisitions
 - 15.5.5 Certifications
- 15.6 GSK plc
 - 15.6.1 Financial Analysis
 - 15.6.2 Product Portfolio
 - 15.6.3 Demographic Reach and Achievements
 - 15.6.4 Mergers and Acquisitions
 - 15.6.5 Certifications
- 15.7 Bausch + Lomb
 - 15.7.1 Financial Analysis
 - 15.7.2 Product Portfolio
 - 15.7.3 Demographic Reach and Achievements
 - 15.7.4 Mergers and Acquisitions
 - 15.7.5 Certifications
- 15.8 Novartis AG
 - 15.8.1 Financial Analysis
 - 15.8.2 Product Portfolio
 - 15.8.3 Demographic Reach and Achievements
 - 15.8.4 Mergers and Acquisitions
 - 15.8.5 Certifications
- 15.9 Sanofi
 - 15.9.1 Financial Analysis
 - 15.9.2 Product Portfolio
 - 15.9.3 Demographic Reach and Achievements
 - 15.9.4 Mergers and Acquisitions
 - 15.9.5 Certifications
- 15.10 Pfizer Inc.
 - 15.10.1 Financial Analysis
 - 15.10.2 Product Portfolio
 - 15.10.3 Demographic Reach and Achievements
 - 15.10.4 Mergers and Acquisitions
 - 15.10.5 Certifications
- 15.11 Fresenius SE & Co. KGaA
 - 15.11.1 Financial Analysis
 - 15.11.2 Product Portfolio
 - 15.11.3 Demographic Reach and Achievements
 - 15.11.4 Mergers and Acquisitions
 - 15.11.5 Certifications

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 15.12 Hikma Pharmaceuticals PLC
 - 15.12.1 Financial Analysis
 - 15.12.2 Product Portfolio
 - 15.12.3 Demographic Reach and Achievements
 - 15.12.4 Mergers and Acquisitions
 - 15.12.5 Certifications
- 16 Middle East and Africa Generic Drugs Market - Distribution Model (Additional Insight)
 - 16.1 Overview
 - 16.2 Potential Distributors
 - 16.3 Key Parameters for Distribution Partner Assessment
- 17 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 18 Company Competitiveness Analysis (Additional Insight)
 - 18.1 Very Small Companies
 - 18.2 Small Companies
 - 18.3 Mid-Sized Companies
 - 18.4 Large Companies
 - 18.5 Very Large Companies
- 19 Payment Methods (Additional Insight)
 - 19.1 Government Funded
 - 19.2 Private Insurance
 - 19.3 Out-of-Pocket

*Additional insights provided are customisable as per client requirements.

* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

Middle East and Africa Generic Drugs Market Report and Forecast 2024-2032

Market Report | 2024-07-19 | 180 pages | EMR Inc.

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$3999.00
	Five User License	\$5299.00
	Corporate License	\$6299.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐ ** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-09"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com